ARCHIVES

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

House subcommittee’s 5.6% Increase For NIH includes $2.5 Billion for NCI

July 18, 1997

Karlan To Succeed Hoskins As Chairman, DOD Ovarian Cancer Program Advisory Panel.

July 27, 2001

Cancer Control Dilemma: What To do With Successful Demonstrations

September 10, 1976

Communication Is Key To Clinical Trial Enrollment

June 30, 2006

NCI Disappointed Over Response To Survey Leads; CRAG Proposals Inadequate, More Will Be Sought

August 6, 1976

NCI Supercomputer To Be Available To Extramural Scientists

June 8, 1984